-
Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland
Oncoscience | October 3rd, 2018
Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingd...
-
Medical Need is the new distribution partner for CIMAher® in the Nordics
Oncoscience | May 21st, 2018
Oncoscience GmbH announced today that it has entered into an exclusive supply and distribution agreement with ...
-
Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.
Oncoscience | November 17th, 2017
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab...
-
legal form changed
Oncoscience | August 22nd, 2017
We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson....
-
Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba
Oncoscience | April 7th, 2016
At this global clinical development meeting, more than 150 researches from over 20 countries discuss the latest results ...
